Galectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Galectin Therapeutics will share an update on its belapectin and MASH programs at an H.C. Wainwright conference webcast on September 14, 2026.

Rhea-AI Summary

Galectin Therapeutics (GALT) will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026, at 11:30 AM ET in New York. The appearance will include a formal company presentation and one-on-one investor meetings, with a live and archived webcast accessible through the conference link and the Events & Presentations page in Galectin’s investor section.

Galectin develops therapeutics targeting galectin proteins, led by belapectin, a galectin-3 inhibitor with U.S. FDA Fast Track designation. The lead program focuses on metabolic dysfunction-associated steatohepatitis (MASH) with cirrhosis and portal hypertension, and additional clinical work is underway in combination immunotherapy for advanced head and neck cancers and other malignancies, with further progress in these areas largely dependent on securing suitable partners.

Key Figures

Presentation date and time: September 14, 2026 at 11:30 AM ET

Presentation date and time

September 14, 2026 at 11:30 AM ET

H.C. Wainwright Global Investment Conference

Key Terms

fast track designation, portal hypertension, galectin-3

3 terms

fast track designation regulatory

"for which it has Fast Track designation by the U.S. Food and Drug Administration."

Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.

portal hypertension medical

"with cirrhosis and portal hypertension, the most advanced form of MASH-related fibrosis."

An increase in blood pressure in the portal venous system — the veins that carry blood from the intestines to the liver — usually caused by scarring or blockage in the liver that acts like a traffic jam in a pipe. It matters to investors because it drives demand for treatments, diagnostics and procedures, influences clinical trial outcomes and regulatory decisions, and can materially affect healthcare costs and a company’s commercial prospects in liver-related therapies.

galectin-3 medical

"inhibits the galectin-3 protein, which is directly involved in multiple inflammatory"

Galectin-3 is a naturally occurring protein found in cells and blood that helps regulate inflammation, scarring (fibrosis), and cell growth; think of it as a cellular “smoke detector” that signals tissue stress or damage. Investors watch galectin-3 because it can serve as a biomarker for disease severity and prognosis—particularly in heart and fibrotic conditions—and because it is a potential target for diagnostics and new therapies, affecting market opportunity and clinical development risks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NORCROSS, Ga., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that company management will present and attend the H.C. Wainwright 28^th Annual Global Investment Conference, taking place September 14-16, 2026 in New York, NY.

Presentation details:
Format: Company presentation and 1 on 1 meetings
Date & time: September 14th, 2026, at 11:30 AM ET
Webcast: https://journey.ct.events/view/c18a40de-8b48-4807-b323-6fd60b6d73a8

The Galectin management team will be available for one-on-one meetings during the conference. Interested investors should contact their representative at H.C. Wainwright.

The live and archived webcast will also be available on the Events & Presentations page in the investors section of the Company’s website.

About Galectin Therapeutics
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin’s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis and portal hypertension, the most advanced form of MASH-related fibrosis. Liver cirrhosis is one of the most pressing medical needs and a significant drug development opportunity. Additional development programs are in treatment of combination immunotherapy for advanced head and neck cancers and other malignancies. Advancement of these additional clinical programs is largely dependent on finding a suitable partner. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at www.galectintherapeutics.com.

Company Contact:
Jack Callicutt, Chief Financial Officer
(678) 620-3186
ir@galectintherapeutics.com 

Investors Relations Contact:
Kevin Gardner
kgardner@lifesciadvisors.com

FAQ

How can investors access Galectin Therapeutics’ presentation webcast at the H.C. Wainwright conference?

The presentation will be available via a live webcast at the conference link provided and as an archived webcast on the Events & Presentations page in the investors section of Galectin Therapeutics’ website.

How can investors arrange one-on-one meetings with Galectin Therapeutics during the conference?

The management team will be available for one-on-one meetings during the event. Interested investors are instructed to contact their representative at H.C. Wainwright to schedule meetings.